ReviewFrontiers in oncology2026
Migrastatics: an overview of the current scenario and future cancer treatments.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis is the main cause of cancer-related death worldwide. Thus, significant efforts have been directed towards inhibiting metastasis to avoid regrowth or relapse after cytostatic and/or cytotoxic cancer treatments. Drugs targeting cell-invasiveness are known as migrastatics and primarily target the cytoskeleton to impair cell motility and/or invasive mechanisms. However, the cytoskeleton is essential to perform many fundamental processes, including cell division. Consequently, migrastatics often prompt high toxicity, among other serious side effects, which have prevented their clinical use to this date. In this review, we present the current migrastatics scenario, including their main limitations, and discuss proposed alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.